NLRP3/AIM2-IN-2（Cat No.:I045194）is a potent, selective dual inhibitor of the NLRP3 and AIM2 inflammasomes, innate immune complexes that trigger caspase-1 activation, leading to IL-1β and IL-18 maturation and pyroptotic cell death. By blocking both pathways, NLRP3/AIM2-IN-2 reduces excessive inflammation implicated in autoimmune, metabolic, and neurodegenerative diseases. It demonstrates strong efficacy in preclinical models of gout, atherosclerosis, and Alzheimer’s disease. This compound is a valuable research tool for studying inflammasome biology and holds therapeutic promise for treating conditions driven by aberrant innate immune activation while maintaining essential antimicrobial immune responses.